Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Transcriptional signature primes human oral mucosa for rapid wound healing.

Iglesias-Bartolome R, Uchiyama A, Molinolo AA, Abusleme L, Brooks SR, Callejas-Valera JL, Edwards D, Doci C, Asselin-Labat ML, Onaitis MW, Moutsopoulos NM, Gutkind JS, Morasso MI.

Sci Transl Med. 2018 Jul 25;10(451). pii: eaap8798. doi: 10.1126/scitranslmed.aap8798.

PMID:
30045979
2.

E1a is an exogenous in vivo tumour suppressor.

Cimas FJ, Callejas-Valera JL, García-Olmo DC, Hernández-Losa J, Melgar-Rojas P, Ruiz-Hidalgo MJ, Pascual-Serra R, Ortega-Muelas M, Roche O, Marcos P, Garcia-Gil E, Fernandez-Aroca DM, Ramón Y Cajal S, Gutkind JS, Sanchez-Prieto R.

Cancer Lett. 2017 Jul 28;399:74-81. doi: 10.1016/j.canlet.2017.04.010. Epub 2017 Apr 15.

PMID:
28416454
3.

Epidermal loss of Gαq confers a migratory and differentiation defect in keratinocytes.

Doçi CL, Mikelis CM, Callejas-Valera JL, Hansen KK, Molinolo AA, Inoue A, Offermanns S, Gutkind JS.

PLoS One. 2017 Mar 16;12(3):e0173692. doi: 10.1371/journal.pone.0173692. eCollection 2017.

4.

mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model.

Callejas-Valera JL, Iglesias-Bartolome R, Amornphimoltham P, Palacios-Garcia J, Martin D, Califano JA, Molinolo AA, Gutkind JS.

Carcinogenesis. 2016 Oct;37(10):1014-25. doi: 10.1093/carcin/bgw086. Epub 2016 Aug 18.

PMID:
27538837
5.

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.

Yamaguchi K, Iglesias-Bartolomé R, Wang Z, Callejas-Valera JL, Amornphimoltham P, Molinolo AA, Cohen EE, Califano JA, Lippman SM, Luo J, Gutkind JS.

Oncotarget. 2016 Mar 8;7(10):10696-709. doi: 10.18632/oncotarget.7372.

6.

MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells.

Cimas FJ, Callejas-Valera JL, Pascual-Serra R, García-Cano J, Garcia-Gil E, De la Cruz-Morcillo MA, Ortega-Muelas M, Serrano-Oviedo L, Gutkind JS, Sánchez-Prieto R.

Oncotarget. 2015 Dec 29;6(42):44095-107. doi: 10.18632/oncotarget.6574.

7.

E1a promotes c-Myc-dependent replicative stress: implications in glioblastoma radiosensitization.

Valero ML, Cimas FJ, Arias L, Melgar-Rojas P, García E, Callejas-Valera JL, García-Cano J, Serrano-Oviedo L, de la Cruz-Morcillo MÁ, Sánchez-Pérez I, Sánchez-Prieto R.

Cell Cycle. 2014;13(1):52-61. doi: 10.4161/cc.26754. Epub 2013 Oct 11.

8.

ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.

Arias-González L, Moreno-Gimeno I, del Campo AR, Serrano-Oviedo L, Valero ML, Esparís-Ogando A, de la Cruz-Morcillo MÁ, Melgar-Rojas P, García-Cano J, Cimas FJ, Hidalgo MJ, Prado A, Callejas-Valera JL, Nam-Cha SH, Giménez-Bachs JM, Salinas-Sánchez AS, Pandiella A, del Peso L, Sánchez-Prieto R.

Neoplasia. 2013 Jun;15(6):649-59.

9.

Control of the epithelial stem cell epigenome: the shaping of epithelial stem cell identity.

Iglesias-Bartolome R, Callejas-Valera JL, Gutkind JS.

Curr Opin Cell Biol. 2013 Apr;25(2):162-9. doi: 10.1016/j.ceb.2013.01.009. Epub 2013 Feb 19. Review.

PMID:
23434069
10.

Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC.

Galan-Moya EM, de la Cruz-Morcillo MA, Llanos Valero M, Callejas-Valera JL, Melgar-Rojas P, Hernadez Losa J, Salcedo M, Fernández-Aramburo A, Ramon y Cajal S, Sánchez-Prieto R.

PLoS One. 2011;6(12):e28406. doi: 10.1371/journal.pone.0028406. Epub 2011 Dec 2.

11.

P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance.

de la Cruz-Morcillo MA, Valero ML, Callejas-Valera JL, Arias-González L, Melgar-Rojas P, Galán-Moya EM, García-Gil E, García-Cano J, Sánchez-Prieto R.

Oncogene. 2012 Mar 1;31(9):1073-85. doi: 10.1038/onc.2011.321. Epub 2011 Aug 15.

PMID:
21841826
12.

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R.

PLoS One. 2009 Jul 1;4(7):e6124. doi: 10.1371/journal.pone.0006124.

13.

E1a gene expression blocks the ERK1/2 signaling pathway by promoting nuclear localization and MKP up-regulation: implication in v-H-Ras-induced senescence.

Callejas-Valera JL, Guinea-Viniegra J, Ramírez-Castillejo C, Recio JA, Galan-Moya E, Martinez N, Rojas JM, Ramón y Cajal S, Sánchez-Prieto R.

J Biol Chem. 2008 May 9;283(19):13450-8. doi: 10.1074/jbc.M709230200. Epub 2008 Mar 3.

14.

c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy.

Galan-Moya EM, Hernandez-Losa J, Aceves Luquero CI, de la Cruz-Morcillo MA, Ramírez-Castillejo C, Callejas-Valera JL, Arriaga A, Aranburo AF, Ramón y Cajal S, Silvio Gutkind J, Sánchez-Prieto R.

Int J Cancer. 2008 Jan 15;122(2):289-97.

Supplemental Content

Loading ...
Support Center